Z. Diamant (Lund, Sweden), T. Möller (Oegstgeest, Netherlands), C. Porsbjerg (Copenhagen, Denmark), I. Eguiluz Gracia (Malaga, Spain)
Late Breaking Abstract - Revisiting interpretation of blood eosinophil counts (BECs): data from Brazil N. Kwon (Brentford, Middlesex, United Kingdom), E. Pizzichini (N/A, Brazil), A. Bansal (Cambridge, United Kingdom), F. Albers (Research Triangle Park, NC, United States of America), N. Barnes (Brentford, Middlesex, United Kingdom), J. Riley (Stevenage, Hertfordshire, United Kingdom), A. Lima-Matos (Bahia, Brazil), E. Ponte (São Paulo, Brazil), A. Cruz (Bahia, Brazil)
| |
Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST J. Corren (Los Angeles, United States of America), M. Castro (Saint Louis, United States of America), J. Maspero (Buenos Aires, Argentina), A. Valero Santiago (Barcelona, Spain), P. Kuna (Lodz, Poland), S. Guillonneau (Chilly-Mazarin, France), Q. Dong (Cambridge, United States of America), C. Taniou (Nanterre, France), H. Staudinger (Bridgewater, United States of America), J. Chao (Tarrytown, United States of America), N. Amin (Tarrytown, United States of America), G. Pirozzi (Bridgewater, United States of America), M. Ruddy (Tarrytown, United States of America), B. Akinlade (Tarrytown, United States of America), N. H. Graham (Tarrytown, United States of America), A. Teper (Bridgewater, United States of America), A. Khan (Chilly-Mazarin, France)
| |
Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST W. Busse (Madison, United States of America), J. Maspero (Buenos Aires, Argentina), C. Katelaris (Sydney, Australia), D. Saralaya (Bradford, United Kingdom), S. Guillonneau (Chilly-Mazarin, France), B. Zhang (Chilly-Mazarin, France), C. Taniou (Nanterre, France), H. Staudinger (Bridgewater, United States of America), J. Chao (Tarrytown, United States of America), N. Amin (Tarrytown, United States of America), G. Pirozzi (Bridgewater, United States of America), M. Ruddy (Tarrytown, United States of America), B. Akinlade (Tarrytown, United States of America), N. H. Graham (Tarrytown, United States of America), A. Teper (Bridgewater, United States of America), A. Khan (Chilly-Mazarin, France)
| |
Assessment of Efficacy Omalizumab Retreatment in Patients With Severe Asthma Y. Havlucu (Manisa, Turkey), A. Yorgancioglu (Manisa, Turkey)
| |
IMPACT OF OMALIZUMAB ON ALLERGIC ASTHMA - THE LAST 10 YEAR M. Araújo Pereira (Braga, Portugal), I. Ladeira (Porto, Portugal), R. Lima (Porto, Portugal), I. Franco (Porto, Portugal), I. Pascoal (Porto, Portugal), A. Carvalho (Porto, Portugal)
| |
The effect of omalizumab on blood eosinophils count in patients with hypersensitivity to non-steroidal anti-inflammatory drugs (NSAID) compare to patients who tolerate NSAID–pilot study I. Kuprys-Lipinska (Lodz, Poland), L. Mastalerz (Cracow, Poland), P. Majak (Lodz, Poland), K. Tyrak (Cracow, Poland), J. Molinska (Lodz, Poland), M. Jonakowski (Lodz, Poland), Z. Kurmanowska (Lodz, Poland), M. Latek (Lodz, Poland), D. Krzyzanowski (Lodz, Poland), A. Zal (Lodz, Poland), P. Kuna (Lodz, Poland)
| |
Is omalizumab response influenced by passive smoking in severe asthma? D. Cavalet Blanco (Porto Alegre, Brazil), L. Martins Becher (Porto Alegre, Brazil), L. Zani Da Silva (Porto Alegre, Brazil), C. Rocha Dullius (Porto Alegre, Brazil), F. Kahan (Porto Alegre, Brazil), S. Rocha Machado (Porto Alegre, Brazil), J. Miguel Chatkin (Porto Alegre, Brazil)
| |
Patients eligible for anti-IL-5/anti-IL-5Ra treatment in a cohort of adult-onset asthma P. Ilmarinen (Seinäjoki, Finland), L. Tuomisto (Seinäjoki, Finland), O. Niemelä (Seinäjoki, Finland), H. Kankaanranta (Seinäjoki and Tampere, Finland)
| |
Effectiveness of anti-IgE and anti-IL-5 treatment in step 5 asthma patients. J. Saji (Kanagawa, Japan), H. Muraoka (Kanagawa, Japan), E. Nishimoto (Kanagawa, Japan), S. Matsuzawa (Kanagawa, Japan), M. Okamoto (Kanagawa, Japan), T. Inoue (Kanagawa, Japan), H. Handa (Kanagawa, Japan), H. Nishine (Kanagawa, Japan), T. Inoue (Kanagawa, Japan), T. Miyazawa (Kanagawa, Japan), M. Mineshita (Kanagawa, Japan)
| |
Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma S. Skrgat (Golnik, Slovenia), P. Girandon Sušanj (Golnik, Slovenia), U. Bidovec Stojkovic (Golnik, Slovenia), P. Korošec (Golnik, Slovenia)
| |
Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody L. Antonicelli (Ancona, Italy), A. Gobbi (Milan, Italy), M. Bilò (Ancona, Italy), M. Garritani (Ancona, Italy), M. Brianzoni (Ancona, Italy), R. Dellacà (Milano, Italy)
| |
Asthma rehabilitation at high vs. low altitude and its impact on exhaled nitric oxide and sensitization patterns: randomized parallel-group trial S. Saxer (Zurich, Switzerland), S. Schneider (Zurich, Switzerland), M. Lichtblau (Zurich, Switzerland), P. Bader (Zurich, Switzerland), P. Appenzeller (Zurich, Switzerland), B. Estebesova (Bishkek, Kyrgyzstan), B. Emilov (Bishkek, Kyrgyzstan), T. Sooronbaev (Bishkek, Kyrgyzstan), S. Micaletto (Zurich, Switzerland), P. Schmid-Grendelmeier (Zurich, Switzerland), K. Bloch (Zurich, Switzerland), S. Ulrich (Zurich, Switzerland)
| |
Increased Severity of Asthma in Atopic Patients with Eosinophilic Granulomatosis with Polyangiitis A. Berti (Milan, Italy), G. Volcheck (Rochester, United States of America), D. Cornec (Brest, France), R. Smyth (Dublin, Ireland), U. Specks (Rochester, United States of America), K. Keogh (Rochester, United States of America)
| |
Application of the ISHAM criteria for diagnosis of ABPA in a clinical cohort at a university teaching hospital R. Banka (Norwich, United Kingdom), A. Kamath (Norwich, United Kingdom)
| |
Effectiveness of itraconazole and systemic steroids in the treatment of ABPA K. Agarwal (Bahadurgarh,, India), G. Bhati (Pune,, India), G. Singh (Delhi,, India), S. Gaur (Greater Noida,, India), A. Chowdhary (Delhi,, India)
| |
The significance of plasma exchange in the treatment of double-positive for ANCA and anti-GBM disease K. Uto (Miyazaki, Japan), S. Yanagi (Miyazaki, Japan), N. Matsumoto (Miyazaki, Japan), M. Nakazato (Miyazaki, Japan)
| |
Comparison of sIgG4 levels among allergic patients and patients during ASIT G. Feyzkhanova (Moscow, Russian Federation), O. Smoldovskaya (Moscow, Russian Federation), S. Voloshin (Moscow, Russian Federation), L. Pavlushkina (Moscow, Russian Federation), E. Antonova (Moscow, Russian Federation), T. Filatova (Moscow, Russian Federation), A. Zasedatelev (Moscow, Russian Federation), A. Rubina (Moscow, Russian Federation)
| |
Immunoglobulin G4-related pneumonitis and myositis: an atypical presentation of an atypical case. N. Thakkar (Mumbai, India), A. Nene (Mumbai, India)
| |
Alpha-1 antitrypsin deficiency and pulmonary morbidity in patients with primary immunodeficiency disease: A single center experience G. Evers (Muenster, Germany), A. Schulze (Muenster, Germany), M. Thrull (Muenster, Germany), G. Lenz (Muenster, Germany), L. Schmidt (Muenster, Germany), M. Mohr (Muenster, Germany)
| |
Immuno-allertypes in non-cystic fibrosis bronchiectasis P. Tiew (singapore, Singapore), M. Mac Aogain (singapore, Singapore), A. Lim (singapore, Singapore), T. Low (singapore, Singapore), G. Tan (singapore, Singapore), T. Hassan (Kuala Lumpur, Malaysia), T. Ong (singapore, Singapore), S. Pang (singapore, Singapore), Z. Lee (singapore, Singapore), X. Gwee (singapore, Singapore), C. Martinus (singapore, Singapore), Y. Sio (singapore, Singapore), A. Matta (singapore, Singapore), T. Ong (singapore, Singapore), L. Tiong (singapore, Singapore), K. Wong (singapore, Singapore), S. Narayanan (singapore, Singapore), V. Au (singapore, Singapore), D. Marlier (singapore, Singapore), H. Keir (Dundee, United Kingdom), J. Abisheganaden (singapore, Singapore), M. Koh (singapore, Singapore), D. Wang (singapore, Singapore), J. Connolly (singapore, Singapore), F. Chew (singapore, Singapore), J. Chalmers (Dundee, United Kingdom), S. Chotirmall (singapore, Singapore)
| |